HeyJaredFrom Models to Medicine
At KAMI Think Tank, we love cutting through the AI hype to showcase where the technology actually stands and how to use it meaningfully within the life sciences.
- Indexed episodes, last 90 days
- 10
- Latest publication
- Sep 16, 2026
- Audience
- Checking…
- Earliest in this view
- Jul 8, 2026
Latest episodes
Episode 24: Beyond Correlation - Teaching AI the Rules of Biology (opens the original)
Read excerpt
This week, we sit down with Jean-Baptiste Morlot of Deep Life, who makes the case that the drug discovery field has been asking the wrong thing of its AI models. Correlation-based machine learning can find patterns, but it can't tell you why a cell is sick or what it would take to make it healthy again. Jean-Baptiste walks us through how single-cell sequencing unlocked the data volume needed to train something far more ambitious: a causal world model of cellular biology that learns the underlyin
Episode 23: When Biologists Start Thinking Like Engineers (opens the original)
Read excerpt
This week, we sit down with Katie Lennon , CSO of Exthymic, who makes a case most bench scientists aren't ready to hear: biology isn't just a discovery discipline anymore. It's engineering. Katie walks us through what it actually looks like to build biology, hardware, and software concurrently, why that requires a shared language across disciplines, and what gets lost when teams hand off instead of collaborate. We also get into the unglamorous side of AI in the lab. More data documentation, peer
Episode 22: The Model Was Never Built for Her (opens the original)
Read excerpt
In this episode of From Models to Medicine, we sit down with Mark Amouzgar , co-founder and CEO of March Health. Mark opens with a striking stat: general-purpose AI models are only about 60% accurate in women's health. Sounding confident isn't the same as being clinically safe, and in this episode he breaks down exactly why generic AI was never built for this. We get into how March Health built a gender-aware digital twin, what it takes to wrap a model in real clinical logic, and why the average
Episode 21: Glass Box Wins - What Pharma Actually Trusts in AI (opens the original)
Read excerpt
In this episode of From Models to Medicine, we sit down with Lavanya Anandan , Head of External Innovation, West Coast at CSL, whose path from bench scientist to Merck Group platform builder to UCSF Innovation Venture startup advisor gives her a rare view of where AI in drug discovery is delivering versus where it's mostly promise. She makes a sharp case that the companies winning in AI-bio aren't necessarily the ones with the best models, and the reason why might surprise you. We get into what
Episode 20: The Build vs. Buy Question Every Pharma Leader is Wrestling With (opens the original)
Read excerpt
We chat with Karl Moritz , CEO of Reliant AI, now part of Cohere, whose career took him from NLP research to McKinsey to building AI infrastructure for drug development. Karl reminds us that clinical trial success rates have been stuck years, and the golden age of AI-powered target discovery isn't fixing it. Karl lays out a sharp framework; own the science, rent the AI plumbing, and explains why building your own data ingestion pipeline is as misguided as writing your own operating system. He's
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
No verified audience measurement yet.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.